Research
William Blair Initiates Aktis Oncology at Outperform
Aktis Oncology, Inc. (AKTS) has an average rating of buy and mean price target of $32.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$AKTS
